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Hypertrophic cardiomyopathy (HCM) is a genetic form of left ventricular hypertrophy, primarily caused by mutations in 
sarcomere proteins. The cardiac remodeling that occurs as the disease develops can mask the pathogenic impact of the 
mutation. Here, to discriminate between mutation-induced and disease-related changes in myofilament function, we 
investigate the pathogenic mechanisms underlying HCM in a patient carrying a homozygous mutation (K280N) in the cardiac 
troponin T gene (TNNT2), which results in 100% mutant cardiac troponin T. We examine sarcomere mechanics and energetics 
in K280N-isolated myofibrils and demembranated muscle strips, before and after replacement of the endogenous troponin. 
We also compare these data to those of control preparations from donor hearts, aortic stenosis patients (LVHao), and HCM 
patients negative for sarcomeric protein mutations (HCMsmn). The rate constant of tension generation following maximal 
Ca2+ activation (kACT) and the rate constant of isometric relaxation (slow kREL) are markedly faster in K280N myofibrils 
than in all control groups. Simultaneous measurements of maximal isometric ATPase activity and Ca2+-activated tension in 
demembranated muscle strips also demonstrate that the energy cost of tension generation is higher in the K280N than in 
all controls. Replacement of mutant protein by exchange with wild-type troponin in the K280N preparations reduces kACT, 
slow kREL, and tension cost close to control values. In donor myofibrils and HCMsmn demembranated strips, replacement of 
endogenous troponin with troponin containing the K280N mutant increases kACT, slow kREL, and tension cost. The K280N 
TNNT2 mutation directly alters the apparent cross-bridge kinetics and impairs sarcomere energetics. This result supports the 
hypothesis that inefficient ATP utilization by myofilaments plays a central role in the pathogenesis of the disease.
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Introduction
Hypertrophic cardiomyopathy (HCM) is a primary disorder 
of cardiac muscle. Traditionally, it has been characterized by 
the presence of unexplained left ventricular (LV) hypertro-
phy, which occurs in the absence of any other known etiology. 
HCM is often familial with autosomal dominant inheritance. 
Linkage studies in the 1980s led to the discovery of pathogenic 
mutations in genes that encode different components of the con-
tractile apparatus, which has been confirmed by recent large-
scale whole-exome sequencing analysis (Alfares et al., 2015). 
This discovery established the paradigm that HCM is a disease 
of the sarcomere.
With the notable exception of the numerous truncation muta-
tions in the gene encoding the thick filament protein cardiac my-
osin binding protein C, for which evidence of haploinsufficiency 
has been generated (Marston et al., 2009; van Dijk et al., 2009), 
most HCM mutations result in stable mutant proteins that are 
incorporated into the sarcomere and may act in a dominant fash-
ion on the contractile performance (Cuda et al., 1993; Bottinelli 
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et al., 1998b). The pathogenic impact of sarcomeric HCM mu-
tations has been varyingly attributed to aberrant cross-bridge 
dynamics, leading to decreased/increased contractility (Cuda et 
al., 1993; Palmiter et al., 2000; Belus et al., 2008; Palmer et al., 
2008), increased intrinsic force of the myosin motor (Seebohm 
et al., 2009; Sommese et al., 2013), and increased sarcomeric Ca2+ 
sensitivity (Bottinelli et al., 1998a; for a review, see Marston et al., 
2012). To reconcile the lack of consistent contractility changes 
in HCM, it has been proposed that HCM sarcomere mutations 
may lead to increased energy cost of force production through 
inefficient or excessive ATPase activity and that this ultimately 
results in an energy deficiency that contributes to the pathogene-
sis of the disease (Ashrafian et al., 2003). Several studies on HCM 
disease mechanisms in patient hearts and animal models support 
this hypothesis (Jung et al., 1998; Crilley et al., 2003; Javadpour et 
al., 2003; Chandra et al., 2005; He et al., 2007; Belus et al., 2008; 
Luedde et al., 2009; Witjas-Paalberends et al., 2014a,b; Ferrantini 
et al., 2017). Though collectively these studies suggest that energy 
deficiency is a primary consequence of the underlying mutation, 
perturbations occurring in cardiomyocyte signaling pathways 
during disease development can lead to cardiac remodeling that 
may exacerbate or counteract mutation-induced alterations.
Homozygous HCM-causing mutations are rare and usually 
have more severe symptoms than heterozygous mutations (Ho 
et al., 2000; Keller et al., 2004). In this study, we investigated sar-
comere mechanics and energetics in isolated myofibrils and de-
membranated multicellular cardiac muscle strips from a unique 
HCM patient with a homozygous charge mutation (K280N) in the 
TNNT2 gene (Sequeira et al., 2013; Messer et al., 2016). As shown 
here, this homozygous mutation results in 100% mutant cardiac 
troponin T (cTnT), and therefore, it represents a unique means 
to avoid the problems of estimating the extent and the variability 
of the expression of the mutant versus WT alleles between and 
within cardiomyocytes (Montag et al., 2018). In addition, with 
100% mutant cTnT, it becomes easier to assess, by the use of tro-
ponin exchange experiments, which changes in contractile func-
tion are directly due to the presence of the mutant protein, rather 
than secondary to cardiac myofilament remodeling. This also has 
the potential to assess how much mutant protein is required to 
significantly perturb sarcomere function.
In this study, experimental data from one single patient have 
been compared with those from different control groups made 
of several subjects. The challenge of performing meaningful sta-
tistics has been faced using a multistep approach in which the 
descriptive statistics and the comparison among groups were fol-
lowed by a sensitivity analysis, where we analyzed subject-spe-
cific random effects, and we individually compared the K280N 
data with those from each control patient.
Materials and methods
Genotyping of a 26-yr-old male HCM patient who underwent 
cardiac transplantation surgery identified a homozygous muta-
tion in TNNT2, the gene encoding cTnT that translates into the 
missense mutation K280N in the predominant cardiac muscle 
isoform (T3; Uniprot ID P45379-6). The heart muscle sample was 
provided by the Sydney Heart Bank (ID 3.166; Li et al., 2013). Tis-
sue from the free LV wall and interventricular septum (IVS) of 
the explanted heart was collected in cardioplegic solution and 
immediately frozen in liquid nitrogen. Samples of nonfailing 
LV or IVS tissue were obtained from five healthy donor hearts, 
nine patients who underwent aortic valve replacement due to 
aortic stenosis (LVHao group), and nine HCM patients without 
an identified sarcomeric gene mutation after screening of nine 
sarcomere genes who underwent myectomy to relieve LV out-
flow tract obstruction (sarcomere mutation–negative; HCMsmn 
group). Written informed consent from each patient was ob-
tained before surgery, and the study was approved by the local 
Ethics Committees. Clinical details of all patients together with 
an extended version of Materials and methods are given in the 
Supplemental material (Table S1).
Mutant expression
Total RNA was extracted from the human heart biopsies, and 
cTnT mRNA was determined by real-time PCR.
TnT was digested with glu-C, and the peptides were analyzed 
by MAL DI-TOF/TOF mass spectrometry. Data were searched 
against a human sequence database containing WT and K280N 
TnT sequences using MAS COT.
SDS PAGE and Western blot analysis were used to estimate 
cTnT protein content relative to actin.
Myofibril experiments
To isolate myofibrils from frozen human cardiac samples and 
perform mechanical experiments, we used previously pub-
lished techniques (Piroddi et al., 2007; Belus et al., 2008). 
Bundles of few myofibrils (25–80-µm long and 1–4-µm wide), 
mounted in a force recording apparatus (15°C; initial sarco-
mere length, ∼2.2 µm), were activated and relaxed by rapidly 
(<5 ms) translating the interface between two flowing streams 
of activating (pCa 4.5) and relaxing (pCa 8.0) solutions across 
the preparation (Colomo et al., 1998). Maximal isometric ten-
sion (P0) and kinetic parameters of maximal tension generation 
(kACT, rate constant of tension generation following Ca2+ acti-
vation; kTR, rate constant of tension redevelopment following 
release–restretch applied to the myofibril under steady-state 
conditions of force generation) were estimated. Specifically, to 
estimate kTR, a sudden (1–2 ms) decrease in length (20% l0) was 
imposed on myofibrils during the steady contraction, bringing 
the initial length of the preparation below the slack value. After 
a period of unloaded shortening, which reduced the number of 
cross-bridges and before unloaded ventricular myofibrils could 
take up the slack (~80 ms), myofibrils were rapidly (1–2 ms) 
stretched back to their original length to mechanically dissoci-
ate the residual acto-myosin bonds. Relaxation parameters were 
measured as follows: Dslow, duration of the slow isometric phase 
of relaxation following sudden Ca2+ removal, measured from 
the start of the solution switch to the tension “give”; slow kREL, 
rate of the slow isometric phase of relaxation estimated from 
the normalized slope of the linear fit to the force trace; fast kREL, 
rate of the fast phase of relaxation estimated from the time 
constant of the exponential fit to the force trace. IVS samples 
were used to prepare myofibrils from the LVHao and HCMsmn 
patients. Both IVS and LV free wall samples were used to isolate 
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myofibrils from the K280N patient and donor hearts. Since no 
differences were found between the parameters measured from 
IVS and LV myofibrils, data from IVS and LV myofibrils of each 
group were pooled.
Tension cost measurement in cardiac strips
The experimental procedures, solutions, and equipment used to 
simultaneously measure maximal tension and ATPase in human 
permeabilized strips from IVS samples of the K280N, HCMsmn, 
and LVHao patients were as described previously (Narolska et al., 
2005; He et al., 2007; Wijnker et al., 2014b; Witjas-Paalberends 
et al., 2014b). Maximal isometric tension and ATP consumption 
were measured at saturating [Ca2+] and 20°C. The length of the 
preparations was adjusted to a sarcomere length of ∼2.2 µm 
(Narolska et al., 2005). The maximal Ca2+-activated ATPase ac-
tivity was normalized to the volume of the muscle strip and sub-
tracted of the basal ATPase activity in relaxing solution.
Recombinant cTn preparation and exchange in myofibrils 
and muscle strips
Recombinant WT human cTnT containing an N-terminal myc-
tag, human K280N mutant cTnT and human WT cTnC and cTnI 
were expressed and purified, and whole WT and mutant Tn 
complexes were reconstituted according to previously described 
techniques (Robinson et al., 2002; Wijnker et al., 2014a,b). Whole 
troponin complex exchange was achieved in human cardiac myo-
fibrils and multicellular muscle strips by mass displacement fol-
lowing protocols adapted from previously described techniques 
(Piroddi et al., 2003; Narolska et al., 2006). Myofibrils were 
always exchanged overnight (o/n) while cardiac strips were ex-
changed for 4 h or o/n. Preparations incubated for the same time 
in the exchange solution without the exogenous cTn complex 
were used as sham-treated controls.
Determination of degree of troponin exchange
The degree of Tn exchange in K280N and donor myofibrils ex-
changed with WT Tn containing recombinant cTnT labeled with 
a Myc-tag was estimated using one-dimensional SDS-PAGE elec-
trophoresis with 15% acrylamide. Densitometric measurements 
of the ratio between the intensities of native cTnT, and α-actinin 
bands were compared in sham-treated and exchanged myofibrils.
In the muscle strips, the amount of endogenous K280N cTn 
complex exchanged with the exogenous WT cTn complex was 
assessed using 13% SDS-polyacrylamide gel and immunoblotting.
The recombinant K280N mutated cTnT did not include a 
Myc-tag. However, the phosphorylated endogenous cTn com-
plex in the HCMsmn was exchanged for the nonphosphorylated 
exogenous recombinant K280N. The amount of exchange was 
determined using ProQ-Diamond phospho–stained gels as de-
scribed previously (Zaremba et al., 2007). The phosphorylation 
signals of the ProQ-Diamond–stained cTnT were normalized to 
the intensities of the SYP RO ruby–stained cTnT to correct for 
protein loading.
Statistics
Data from myofibrils and muscle strips are expressed in Table 1, 
Table 2, and Table 3 as means ± SEMs. Statistical analysis, taking 
into account non-Gaussian distribution, inequality of variances, 
and within-subject correlation, was performed as detailed in the 
Supplemental material. In brief, data from one single HCM pa-
tient, i.e., the K280N cTnT homozygous patient (Group 1), were 
compared with those from different groups of control patients 
(HCMsmn, Group 2; donors, Group 3; and LVHao, Group 4). For 
each measured parameter, statistical analysis was initially per-
formed by comparison among groups. Repeated measurement 
ANO VA and Kruskal-Wallis rank-sum test were used to evaluate 
differences among the four groups. Post-hoc multiple compar-
isons were performed when ANO VA indicated the presence of 
significant differences among groups (Graph S1[1]). We used the 
Benjamini-Hochberg approach (Benjamini and Cohen, 2017) and 
calculated the corresponding adjusted P values. A false discov-
ery rate (FDR) of 0.05 was used as a cut off for rejection. When 
comparing K280N data with the control groups in the repeated 
measurement ANO VA, we assumed homogeneous within-sub-
ject correlation because the K280N group was constituted by a 
single subject. Thus, for sensitivity analysis, we fitted a linear 
mixed model with patient-specific random effect and omitted 
the group membership indicator. We analyzed subject-specific 
random effect residuals from the fitted linear mixed model data 
to identify differences between subjects that were not related to 
group belonging (Graph S2[1]). Finally, to better investigate the 
differences between the K280N patient and the other subjects 
that were not group related, we treated patient indicator as a 
fixed effect and fitted a one-way ANO VA with post-hoc compar-
ison. As above, to correct for multiple testing, we used the Ben-
jamini-Hochberg approach (Benjamini and Cohen, 2017) and 
calculated the corresponding adjusted P values. An FDR of 0.05 
was used as a cut off.
In the cTn exchange experiments, differences between groups 
of myofibrils or muscle strips (exchanged vs. sham-treated un-
exchanged controls) were analyzed using Student’s t test for un-
paired observations.
Online supplemental material
Supplemental text, graphs, tables, and figures are included in a 
separate Microsoft Word file. In the Online supplemental mate-
rial, clinical details of all patients used in this study are given 
together with an extended version of Materials and methods and 
a detailed description of the statistical analysis.
Results
Clinical characteristics of patient and identification of 
homozygous cTnT K280N mutation
A 23-yr-old man with progressive worsening of dyspnea on effort 
was diagnosed with HCM. Because of severe resting outflow tract 
obstruction, he underwent surgical septal myectomy. In the next 
few years, he became severely symptomatic, and at 26-yr of age, 
he was transplanted. Pathological examination of the explanted 
heart confirmed the diagnosis of severely obstructive HCM. The 
heart displayed marked asymmetric hypertrophy of the IVS 
(maximum thickness, 37 mm) and posterior LV wall (maximum 
thickness, 27 mm). Right ventricular wall was up to 10-mm thick. 
An adverse-restrictive evolution was observed, characterized 
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by small-sized LV cavity (i.e., LV end diastolic diameter was 46 
mm; LV end systolic diameter was 23 mm). Despite resting LV 
ejection fraction measurements showing supernormal values 
(>70%), cardiac stroke volume was extremely reduced (<50 ml/
beat), leading to severe heart failure symptoms (New York Heart 
Association Heart Failure Classification IV). Histological sections 
showed diffuse cardiomyopathic features: moderate fiber disar-
ray in the septum, a moderate degree of anisocytosis (2+), mild 
myocytolysis (1+), and a moderate diffuse degree of interstitial fi-
brosis (2+). There was no indication of inflammation, and stains 
for iron and amyloid were negative.
Genotyping indicated a novel homozygous missense mutation 
c.804G>T in the TNNT2 gene predicted to produce a K280N mu-
tant in cTnT. The homozygous mutation was confirmed at the 
mRNA level (Fig. 1 A) and at the protein level by mass spectrom-
etry, where the K280N variant was detected, and the WT protein 
was undetectable (Fig. 1 B). Western blot analysis showed that the 
protein content of cTnT relative to actin was indistinguishable 
in K280N and donor samples indicating that there was no hap-
loinsufficiency and that the mutant cTnT could act as a poison 
peptide (Fig. 2).
Impact of K280N cTnT mutation on myofibril 
mechanics and kinetics
Fig. 3 shows representative traces of tension responses to max-
imal Ca2+ activation by fast solution, switching for K280N and 
aortic stenosis (LVHao) myofibrils. Average data for both myofi-
bril groups are shown in Table 1, together with data of myofibrils 
taken from donors and HCMsmn patients (for statistics, see tables 
and graphs in Supplemental statistics). In the K280N myofibrils 
resting tension (RT) was higher, compared with all control myo-
fibril groups, although the difference between K280N and LVHao 
myofibrils was uncertain because of the rather large variability 
among patients of the LVHao group (Graph S2[1] and Table S2[1]). 
Maximal active tension (P0) of K280N myofibrils was not sig-
nificantly different from that of the three control groups. The 
kinetics of tension generation, kACT (as well as kTR; see Tables 
S1[4] and S2[4] and Graphs S1[4] and S2[4]), of K280N myofi-
brils were markedly faster compared with those of the three con-
trol myofibril groups (Table 1 and Fig. 2 C), indicative of faster 
cross-bridge turnover rate. The kinetics of full tension relaxation 
with step reduction of [Ca2+] are shown on a faster time scale in 
Fig. 2 D for LVHao and K280N myofibrils. As previously described 
(Piroddi et al., 2007; Belus et al., 2008), the time course of force 
relaxation in human cardiac myofibrils was biphasic. It has been 
shown (Poggesi et al., 2005; Stehle et al., 2009) that the early slow 
relaxation phase occurs while sarcomeres are isometric, and its 
rate constant (slow kREL) is predominantly the apparent rate with 
which attached cross-bridges leave force-generating states. The 
fast exponential phase follows the “give” of a few sarcomeres 
and is dominated by intersarcomere dynamics. Slow kREL was 
markedly faster in the K280N myofibrils than in all three control 
groups (Table 1), indicative of faster cross-bridge detachment 
under isometric conditions. The duration of the slow relaxation 
phase and the rate constant of the fast relaxation phase (fast 
kREL), instead, were not significantly different in the K280N 
Table 1. Mechanical and kinetic parameters of myofibrils from the homozygous K280N cTnT HCM patient and different groups of control patients 
(top four rows of data) and impact of cTn exchange in K280N and donor myofibrils (bottom six rows of data)
Myofibril type RT P0 kACT Dslow slow kREL fast kREL
kN m−2 kN m−2 s−1 ms s−1 s−1
Donors (N = 5) 10.4 ± 0.6 (n = 98) 111 ± 5 (n = 96) 0.85 ± 0.02 (n = 118) 186 ± 5 (n = 100) 0.29 ± 0.02 (n = 95) 4.18 ± 0.14 (n = 101)
LVHao (N = 7) 9.8 ± 1.1 (n = 48) 96 ± 6 (n = 58) 0.71 ± 0.04 (n = 50) 248 ± 13 (n = 54) 0.20 ± 0.02 (n = 54) 3.15 ± 0.20 (n = 54)
HCMsmn (N = 3) 8.2 ± 0.9 (n = 44) 87 ± 7 (n = 43) 0.74 ± 0.03 (n = 45) 206 ± 7 (n = 44) 0.30 ± 0.02 (n = 44) 4.62 ± 0.20 (n = 44)
K280N (N = 1) 14.9 ± 1.4* (n = 43) 87 ± 5 (n = 43) 1.73 ± 0.07* (n = 39) 226 ± 11 (n = 43) 0.63 ± 0.05* (n = 42) 3.76 ± 0.16 (n = 42)
Tn-exchanged batches
K280N sham treated 
(N = 1)
15.9 ± 2.9 (n = 12) 89 ± 9 (n = 12) 1.69 ± 0.08 (n = 17) 240 ± 16 (n = 16) 0.69 ± 0.08 (n = 16) 3.90 ± 0.27 (n = 16)
K280N WT Tn exch 
(N = 1)
15.7 ± 2.0 (n = 13) 86 ± 7 (n = 14) 1.00 ± 0.09++ (n = 16) 259 ± 27 (n = 15) 0.31 ± 0.05++ (n = 16) 3.13 ± 0.19+ (n = 16)
Donors sham treated 
(N = 2)
10.5 ± 0.83 (n = 64) 114 ± 7 (n = 62) 0.86 ± 0.03 (n = 70) 173 ± 6 (n = 62) 0.28 ± 0.02 (n = 58) 4.26 ± 0.18 (n = 63)
Donors WT Tn exch 
(N = 2)
10.1 ± 0.7 (n = 72) 91 ± 6+ (n = 63) 0.84 ± 0.03 (n = 70) 179 ± 8 (n = 59) 0.30 ± 0.02 (n = 66) 4.65 ± 0.19 (n = 65)
Donor sham treated 
(N = 1)
10.8 ± 1.1 (n = 14) 94 ± 10 (n = 14) 0.81 ± 0.04 (n = 15) 214 ± 7 (n = 15) 0.33 ± 0.04 (n = 15) 3.78 ± 0.32 (n = 15)
Donor K280N Tn exch 
(N = 1)
15.9 ± 1.9+ (n = 12) 77 ± 9 (n = 10) 1.04±0.08++ (n = 12) 186 ± 9+ (n = 12) 0.60 ± 0.07++ (n = 13) 4.18 ± 0.62 (n = 13)
Means ± SE; N, number of patients in the group; n, number of myofibrils; P0, maximal Ca2+-activated tension. For the statistics of the comparison between 
groups in the first four rows, see Supplemental materials; *, K280N parameters for which the statistical analysis shows a significant difference versus all 
control groups. For the statistics of the cTn exchange experiments (bottom six rows): +, P < 0.05; ++, P < 0.01 Student’s t test for unpaired observations 
(exchanged myofibrils vs. sham-treated unexchanged myofibrils).
Piroddi et al. 
Impaired myofilament energetics in HCM
Journal of General Physiology
https://doi.org/10.1085/jgp.201812160
5
myofibrils compared with the three control groups (Table 1 and 
Supplemental statistics).
Replacement of most mutant cTnT (~70%; Fig.  4  A) by ex-
change of the endogenous Tn complex for a recombinant human 
WT cTn complex into the homozygous K280N myofibrils reduced 
kACT and slow kREL close to control values without affecting myo-
fibril active and resting tension (P0 and RT; Figs. 4, B and C; and 
Table 1). As previously reported, replacement of the endogenous 
cTn with the recombinant human WT complex into donor myo-
fibrils had no effects on force kinetics (Figs. 4, B and C), though 
it could slightly reduce maximal tension (Table 1).
Replacement by exchange of the endogenous cTn complex 
for a recombinant human cTn complex containing the K280N 
mutant cTnT into donor myofibrils significantly acceler-
ated kACT and increased slow kREL and RT close to the values 
found in the myofibrils from the K280N patient (Figs. 4, B and 
C; and Table 1).
This result obtained from myofibrils demonstrates that the 
kinetic changes observed in the homozygous K280N human sam-
ple are directly related to the presence of the mutant protein. 
Together with kACT (as well as kTR), slow kREL is especially affected 
by the K280N cTnT form suggesting that faster cross-bridge de-
tachment rate, and therefore, increased energy cost of tension 
generation are primary effects of the mutation.
Impact of the K280N TnT mutation on sarcomeric tension cost
Direct demonstration of the impact of the K280N mutation on 
the energy cost of tension generation was given with a series 
of experiments in which tension and ATPase activity were si-
multaneously measured in demembranated muscle strips from 
the K280N homozygous HCM patient, from two donors, from 
three LVHao patients, and from six HCMsmn patients. The ratio 
between maximal ATPase activity and active tension generation, 
representing the energetic cost of tension generation, was sig-
nificantly higher in the K280N compared with control muscle 
strips (Table 2 and Table S2[8]). While the sensitivity analysis 
for the parameter tension cost confirmed the presence of a sys-
tematic increase in K280N compared with both donors, four over 
six HCMsmn and two over three LVHao, statistical differences in 
maximal tension and maximal ATPase activity were uncertain 
because of variability issue (see Supplemental statistics). No 
systematic differences were found in the resting ATPase activity 
between the K280N and the control groups (Table 2 and Supple-
mental statistics).
Replacement of the mutant cTnT for the WT cTnT by cTn 
exchange in the K280N muscle strips lowered the maximal 
ATPase activity without affecting maximal tension (Figs. 5, A 
and B). As a result, the high tension cost of the K280N cardiac 
muscle was rescued to values closer to those measured in LVHao 
Figure 1. Identification of homozygous cTnT 
K280N mutation. (A) Sequence of the TNNT2 
mutation at the mRNA level. The complete 
substitution of guanine residue at position 840 
predicts a homozygous change of amino acid 
from a lysine (K) to an asparagine (N) at posi-
tion 280. (B) MAL DI-MS mass spectrometry of 
purified troponin from the HCM sample show-
ing TnT part of the spectrum. The predicted WT 
human TnT peptide corresponds to an m/z ratio 
of 3,279.8984; the predicted mutated peptide 
sequence corresponds to a peptide ion with m/z 
ratio of 3,265.8464. The spectrum shows peaks 
for the reporter mutated peptide at 3,265 (red 
arrow) and the virtual absence of signal at 3,279 
(blue arrow) for WT peptide. Tandem mass spec-
trometry analysis confirmed the mutated peptide 
sequence. The absence of the predicted WT pep-
tide indicates that the sample has a homozygous 
mutation. Modified from Messer et al. (2016) sup-
plementary data.
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and HCMsmn preparations (Fig. 5 C and see Table 2). The effect 
reached significance in case of the o/n exchange procedure. 
The amount of endogenous K280N cTnT replaced by exogenous 
WT cTnT was ∼50% after 4 h exchange and >80% after o/n ex-
change (Fig. 5 D).
Replacement of the endogenous cTnT by the exogenous re-
combinant K280N cTnT by cTn exchange in HCMsmn preparations 
did not significantly modify maximal tension and maximal AT-
Pase activity (Figs. 5, E and F), but tended to increase tension cost 
in the 4 h exchanged HCMsmn muscle strips (Fig. 5 G). The amount 
of endogenous cTnT in the HCMsmn muscle strips exchanged after 
4 h by the recombinant exogenous K280N cTnT yielded ∼50% 
based on cTnT phosphorylation differences (Fig. 5 H).
All together Tn replacement experiments in the strips indi-
cate that >50% of the mutant protein is needed to significantly 
increase tension cost.
Discussion
Previously reported data from the same homozygous patient 
(Sequeira et al., 2013; Messer et al., 2016) had a different focus, 
i.e., the impact of HCM mutations on length dependent activation 
and post-translational changes of regulatory proteins. Here, we 
focus on kinetic and energetic parameters measured at maximal 
Ca2+ activation and optimum myofilament overlap that are either 
unaffected or are scarcely affected by post-translational changes 
of regulatory proteins. We compared human cardiac sarcomeres 
expressing 100% of the K280N cTnT mutation with those from 
several reference groups of patients and found that the muta-
tion is specifically associated with large changes in cross-bridge 
kinetics. These changes do not affect maximal tension, but lead 
to increased energy cost of tension generation. Tn replacement 
experiments show that the sarcomere kinetic and energetic 
changes are primary effects of the HCM-associated K280N cTnT 
mutation rather than secondary effects of disease-related re-
modeling. Faster cross-bridge detachment under isometric con-
ditions and higher energy cost of tension generation may be a 
common feature to several HCM-associated mutations (Belus 
et al., 2008; Ferrantini et al., 2009; Luedde et al., 2009; Witjas-
Paalberends et al., 2013, 2014b).
The K280N is a novel mutation in cTnT. The clinical features 
of the patient and the biophysical phenotype of his cardiac tissue 
Figure 2. Western blot analysis to determine the level 
of cTnT in the K280N sample (LV and IVS; both in dupli-
cate) compared with donor samples (n = 2 in duplicate). 
(A) The Ponceau-stained blot shows equal loading of sam-
ples. (B and C) The blot was stained with anti-actin and 
anti-troponin T antibody to calculate the ratio between 
cTnT and actin, which did not differ between K280N and 
donor samples (C). a.u., arbitrary units.
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Figure 3. Impact of K280N cTnT mutation on myofibril mechanics and kinetics. (A and B) Representative records of maximum tension activation and full 
relaxation in response to sudden pCa changes by fast solution switching in K280N (A) and LVHao (B) myofibril preparations. pCa changes at arrows as indicated. 
Lower traces show fast release–restretch protocol for kTR registration at steady Ca2+-activation. (C and D) Time courses of tension activation (C) and relaxation 
(D) of K280N and LVHao myofibrils superimposed after normalization to maximal tension (same traces as in A and B on faster time base).
Figure 4. cTn replacement in K280N myo-
fibrils. (A) 15% SDS-PAGE gel of unexchanged 
K280N myofibrils (first lane), WTcTn exchanged 
K280N myofibrils (second lane), and WT recom-
binant cTn with Myc-tag cTnT (third lane). The 
extent of the exchange estimated from the 
intensity ratio of the endogenous cTnT band to 
the α-actinin band in the first two lanes was 
around 70%. (B and C) Effects of Tn replace-
ment by exchange on kACT (B) and slow kREL 
(C) of K280N (first two columns in each panel) 
and donor myofibrils (last four columns in each 
panel). Donor myofibrils were exchanged either 
with WT Tn (third and fourth column) or K280N 
Tn (last two columns). Bars are SEM. **, P < 
0.01. Student’s t test for unpaired observations 
(exchanged myofibrils vs. sham-treated unex-
changed myofibrils).
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that can be rescued by Tn replacement strongly suggest that the 
novel mutation is pathogenic for HCM. HCM is generally caused 
by the autosomal dominant action of heterozygous mutations 
and the finding of homozygous mutations is very rare. Homozy-
gous carriers of HCM sarcomeric mutations have been previously 
reported to develop more severe phenotypes compared with het-
erozygous carriers (Ho et al., 2000; Lin et al., 2000; Richard et 
al., 2000; Knöll et al., 2010). In particular, there have been two 
previous reports of homozygous mutations in TNNT2 (Ho et al., 
2000; Lin et al., 2000). In the case of the S179F cTnT mutation 
(Ho et al., 2000), the single affected individual had severe HCM 
with sudden death at age 17, and three heterozygous siblings and 
one parent were asymptomatic (the other parent had exertional 
chest pain). In the second case, 11 members of a Japanese family 
carried the F110I cTnT mutation (Lin et al., 2000). Cardiac hyper-
trophy and other clinical features were severe in the two subjects 
homozygous for the mutation, while the nine heterozygous sub-
jects either suffered from less severe disease or showed no clear 
evidence of hypertrophy. Unfortunately, family information is 
not available for the K280N proband in this study. However, the 
early and severe clinical phenotype of the K280N patient seems 
to confirm previous observations of the severity of homozygous 
mutations. The demonstration that the homozygous K280N mu-
tation resulted in 100% mutant cTnT with no evidence of haplo-
Table 2. Mechanical and energetic parameters of permeabilized ventricular strips from the homozygous K280N cTnT HCM patient and three groups 
of control patients
K280N (N = 1, n = 16) Donors (N = 2, n = 12) LVHao (N = 3, n = 13) HCMsmn (N = 6, n = 29)
Maximal tension (kN m−2) 13.5 ± 1.8* 38.7 ± 1.2 21.3 ± 1.5 25.6 ± 1.6
Maximal ATPase activity (μmol L−1 s−1) 38.4 ± 4.8 91.0 ± 4.7 52.2 ± 6.3 45.2 ± 2.7
Tension cost (μmol L−1 s−1/ kN m−2) 3.1 ± 0.3* 2.3 ± 0.1 2.5 ± 0.3 1.8 ± 0.1
Basal ATPase activity (μmol L−1 s−1) 4.6 ± 0.8 10.9 ± 2.1 10.3 ± 2.2 7.2 ± 1.0
Means ± SE; N, number of patients in the group; n, number of muscle strips. For the statistics of the comparison between groups, see Supplemental 
materials; *, K280N parameters for which the statistical analysis shows a significant difference versus control groups.
Figure 5. Impact of K280N cTnT mutation on skinned myocardium mechanics and energetics. (A–C) Tn replacement by exchange with WT Tn in K280N 
demembranated muscle strips. Impact of 4-h and o/n exchange protocols on maximal tension (A), maximal ATPase (B), and tension cost (C). Tn-exchanged 
preparations (K280N+WT Tn) are compared with the corresponding sham-treated unexchanged preparations (K280N). *, P < 0.05. Student’s t test for unpaired 
observations. (D) Replacement of the endogenous mutant Tn with WT Tn containing cTnT labeled with a Myc-tag was assessed in K280N muscle strips after 4 h 
and o/n exchange using 13% SDS-polyacrylamide gel and immunoblotting. (E–G) Tn replacement by exchange with K280N Tn in HCMsmn demembranated muscle 
strips. Impact of 4-h exchange protocol on maximal tension (E), maximal ATPase (F), and tension cost (G). K280N Tn-exchanged preparations (HCMsmn+K280N Tn) 
are compared with sham-treated unexchanged HCMsmn preparations (HCMsmn). (H) The amount of exchange was determined using ProQ-Diamond phospho–
stained one-dimensional gels (left). The phosphorylation signals of the ProQ-Diamond–stained cTnT were normalized to the intensities of the SYP RO Ruby 
stained cTnT (right) to correct for protein loading.
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insufficiency further supports the idea of a gene dose–dependent 
effect of HCM mutations on the severity of the phenotype.
For comparison with the data from the K280N myofibrils 
here we used tissue from different “control” groups. Samples 
from donor hearts could be taken, in principle, as the example 
of healthy nonhypertrophic nonfailing cardiac muscle. However, 
potential problems related to the use of cardiac samples from ex-
planted hearts that are not used for transplantation for techni-
cal reasons have raised some concerns (Marston and de Tombe, 
2008). The variability among different donors in the parameters 
describing overall myofibril relaxation (Dslow and fast kREL) may 
be related to some of those concerns (see Supplemental statis-
tics). LVHao patients present with hypertrophic phenotype, and 
their IVS tissue may share some features of the cardiac muscle re-
modeling observed in HCM patients. LVHao seems to be the most 
heterogeneous of the control groups; several parameters (e.g., 
myofibril RT and kinetic parameters) show a variability among 
patients that is larger than that observed in the other control 
groups (see Supplemental statistics). The HCMsmn patients do 
not harbor a sarcomeric gene mutation after thoroughly screen-
ing nine genes, but present with a similar clinical phenotype as 
the HCM patients carrying myofilament protein mutations. This 
suggests they could be the best reference group when seeking for 
the direct impact of a mutant protein associated with HCM. In-
dependent of the above considerations, the kinetics of force gen-
eration (kACT) and isometric relaxation (slow kREL) of the K280N 
myofibrils significantly differed from those of each patient of all 
control groups (see Supplemental statistics).
The markedly enhanced slow kREL found in the K280N myo-
fibrils indicates that the rate of cross-bridge detachment under 
isometric conditions is accelerated by the mutation (Poggesi et 
al., 2005; Stehle et al., 2009) though other relaxation parameters 
(Dslow and fast kREL) are unaffected (Fig. 3 and Table 1). Cross-
bridge detachment rate can in principle affect all relaxation pa-
rameters, but a strict correlation between slow kREL, Dslow, and fast 
kREL is not necessarily expected. The duration of the slow initial 
phase of relaxation is dependent on the ability of the sarcomeres 
to remain isometric, and changes in sarcomere homogeneity can 
affect both the time of appearance of the tension shoulder (Dslow) 
and the intersarcomere dynamics that dominate fast kREL. In ad-
dition, both Dslow and fast kREL, at variance with slow kREL, are sen-
sitive to the possibility that a few force generating cross-bridges 
can still be formed after sudden Ca2+ removal because of im-
paired thin filament switch off mechanisms (Poggesi et al., 2005; 
Stehle et al., 2009). The K280N cTnT mutation appears to impact 
myofibril RT that is consistently higher in the mutant myofibrils 
compared with controls (Table 1). The mechanism underlying 
the increase in RT associated with the K280N mutation has not 
been investigated in the present study, but residual cross-bridge 
attachment may contribute to increase myofibril tension in the 
virtual absence of Ca2+. Replacement of most mutant protein for 
the WT form in the K280N myofibrils was unable to reduce RT 
(Table 1). However, replacement of the endogenous WT Tn with 
the K280N mutant complex into donor myofibrils did signifi-
cantly increase RT (Table 1). These apparently contrasting results 
suggest that a modest amount of the mutant protein is enough to 
impair contraction switch off and increase myofibril tension in 
the virtual absence of Ca2+. The amount of Tn replacement was 
never 100% and varied with experimental conditions (e.g., Figs. 
4, D and H; and Fig. S1). Specific changes due to the mutation may 
be differently related to the amount of mutant protein present 
in the sarcomere. Further work, however, is required to better 
investigate this issue.
The K280N mutation in cTnT accelerates cross-bridge ki-
netics, which is supported by the markedly enhanced kACT and 
slow kREL reported here, but does not change myofibril maximal 
force (Fig. 3 and Table 1). According to a simple two-state cross-
bridge model (Brenner, 1988), force-activation kinetics reflect 
cross-bridge turnover rate, and under the present experimental 
conditions (nominally zero [Pi]), kACT reports the sum of the ap-
parent rate constants fapp and gapp that rate limit the transition 
of cross-bridges from nonforce-generating to force-generating 
states and from force-generating to nonforce-generating states, 
respectively. In terms of cross-bridge turnover kinetics, slow kREL 
is a measure of gapp that in the model is also equal to the tension 
cost (isometric ATPase per unit force). Force is proportional to 
the apparent duty ratio [fapp / (fapp + gapp)], and an increase in gapp 
should lead to a decline in the force generating capacity of the 
sarcomere, unless the increase in gapp is compensated for by an 
increase in fapp. Estimating fapp from the difference between kACT 
and slow kREL and gapp from slow kREL yields duty ratios that are 
not significantly different in K280N versus all control groups of 
myofibrils (Table 3). Our analysis reveals that the estimated fapp 
is significantly higher in the K280N myofibrils than in the myofi-
brils of all control groups. Myofibril kinetic data support the idea 
that the K280N mutation does increase fapp (two- to threefold) 
Table 3. Estimate of the apparent rate of cross bridge attachment (fapp) and duty ratio (proportional to maximal tension) from myofibril kinetic 
measurements
Myofibril type gapp (α Tc) fapp Estimated duty ratio (α P0)
slowkREL (kACT-slow kREL) (fapp/fapp+gapp)
Donors (N = 5) 0.29 ± 0.02 (95) 0.55 ± 0.03 (93) 0.63 ± 0.02 (93)
LVHao (N = 7) 0.20 ± 0.02 (54) 0.39 ± 0.04 (34) 0.675 ± 0.05 (34)
HCMsmn (N = 3) 0.30 ± 0.02 (44) 0.43 ± 0.04 (42) 0.56 ± 0.04 (42)
K280N (N = 1) 0.63 ± 0.05* (42) 1.14 ± 0.08 (38)* 0.635 ± 0.03 (38)
Means ± SE; N, number of patients in the group; numbers in parenthesis are the numbers of myofibrils in each group. *, fapp is significantly higher in K280N 
myofibrils versus all control groups.
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besides increasing gapp (two- to threefold) with no impact on sar-
comere force generation.
Following Ca2+-activation, fapp (the probability of the cross-
bridge transition to force-producing states) behaves as a second 
order rate constant that can be regarded as the product of the 
fraction of acto-myosin complexes in a preforce-generating state 
available for force generation multiplied by the rate constant of 
the forward transition from this preforce state to force states. 
One possibility is that the K280N cTnT mutation increases the 
fraction of the acto-myosin complexes available for force gen-
eration at maximal Ca2+ activation rather than their forward 
transition rate constant. As to the impact of the mutation on gapp 
shown by present results, pioneer studies (Potter et al., 1995; 
Bing et al., 1997; Sweeney et al., 1998) reviewed by Gordon et 
al. (2000) reported that HCM-associated cTnT mutations may 
cause changes in regulated acto-S1 ATPase and unloaded thin 
filament sliding speed. This implies that cTnT can modulate the 
cross-bridge kinetics of the strongly bound state in addition to 
its ability to control the attachment of cross-bridges to the thin 
filament. Potential molecular mechanisms of the effects of the 
K280N mutation remain, however, unclear also because the ex-
treme C-terminal domain of cTnT could not be resolved in the ex-
tant structures (Takeda et al., 2003), because of the high degree 
of inherent protein flexibility required to modulate the physical 
position of Tm in response to Ca2+ binding.
In K280N multicellular strips, at variance with myofibrils, 
maximal force was lower than in HCMsmn and LVHao (though 
sensitivity analysis makes the difference vs. the LVHao group un-
certain). Myocardial remodeling such as cellular hypertrophy, 
lower myofibrillar density, and fibrosis may contribute to lower 
maximal force in the K280N multicellular preparations. Indeed, 
a decrease in myofibrillar density has previously been correlated 
with the decrease in the maximal force generating capacity of 
skinned cardiomyocytes from HCM patients carrying different 
mutations (Witjas-Paalberends et al., 2013). However, tension 
cost measurements and the results of Tn replacement experi-
ments in skinned strips of cardiac muscle substantiate the idea 
that the K280N mutation primarily increases the energetic cost 
of tension generation by increasing the rate of force generating 
cross-bridge detachment.
Study limitations
One limitation of the present study is the fact that a single HCM 
patient carrying a novel pathogenic cTnT mutation has been inves-
tigated. At present, no possibility to recruit additional homozygous 
patients with this K280N mutation exists. Performing a meaning-
ful statistics to compare the study group (K280N) constituted by 
a single patient with control groups (donors, HCMsmn, and LVHao) 
constituted by a variable number of subjects is challenging and we 
had to use a multistep procedure, illustrated in details in the Sup-
plemental material and summarized in the Materials and methods. 
As a final step of this statistic procedure, we performed a sensitiv-
ity analysis, and we looked for the presence of individual differ-
ences between subject 1 (K280N) and the several control subjects, 
not related to group identity. This sensitivity analysis allowed us to 
conclude for a systematic difference between K280N and controls 
for three parameters: kACT, slow kREL, and tension cost.
Sarcomere post-translational changes were not investigated 
in this study. In particular, differences in the phosphorylation 
status of the sarcomeric proteins may alter the kinetics of acti-
vation and relaxation (Rao et al., 2014), though protein kinase 
A treatment seems unable to affect the kinetics of force genera-
tion and relaxation of human cardiac myofibrils (Walker et al., 
2011). Similar cTnI phosphorylation levels were observed in the 
K280N and donor samples (unpublished data), suggesting that 
the large kinetic differences found in the K280N myofibrils 
compared with donors cannot be explained by differences in the 
sarcomere phosphorylation status. Importantly, the lack of im-
pact of recombinant unphosphorylated WT Tn exchanged into 
donor myofibrils on force kinetics argues against a significant 
effect of cTnI phosphorylation on human cardiac myofibril ki-
netics. Among control groups used in the present study, we had 
previously reported differences in the phosphorylation status 
(van Dijk et al., 2012) that do not result here into force kinetic 
changes of maximally activated myofibrils. For instance, protein 
kinase A phosphorylation of cTnI in HCMsmn samples was signifi-
cantly lower compared with donors (van Dijk et al., 2012), while 
kACT and slow kREL were the same (Table 1). Our results indicate 
that cTnI phosphorylation status does not alter kinetics and ten-
sion cost of maximally activated cardiac preparations, which is 
in line with results of Walker et al., 2011. In human septal HCM 
samples from patients with thick-filament mutations, we pre-
viously identified significant post-translational modifications 
in Excitation Contraction Coupling and sarcolemmal proteins 
caused by a maladaptive change in calcium-/calmodulin-depen-
dent protein kinase II (CaMKII) signaling (Coppini et al., 2013). 
Similar variations of CaMKII activity were observed in two HCM 
mouse models carrying different TNNT2 mutations (R92Q and 
E163R; Coppini et al., 2017; Ferrantini et al., 2017). We cannot 
exclude CaMKII-related changes in the K280N myocardium, but 
it is unlikely they are responsible for the sarcomere kinetic and 
energetic alterations reported in the present work.
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